The first domestic oral resilience anti -new crown drug was approved

On the 25th, the State Drug Administration was approved by the special approval procedures for the drug, and the emergency conditional conditions were approved by the Azf fixed chip of Henan Real Biotechnology Co., Ltd.

This drug is the treatment of oral small molecular virus pneumonia for oral small molecular virus pneumonia. On July 20, 2021, the State Drug Administration has attached conditions to approve adult HIV-1 infection patients with the treatment of high virus loads with other reverse-translitease inhibitors. This is an attachment to approve new indications for the treatment of adult patients in ordinary new coronary virus pneumonia. Patients should be used strictly under the guidance of the doctor.

The State Drug Administration requires listing permit holders to continue to carry out relevant research work, complete the requirements for qualified conditions within a time limit, and submit subsequent research results in a timely manner.

Source: Xinhua View Point

Reporter: Dai Xiaohe

Responsible editor: Zhang Ziqing

School pair: Guo Yanhui Meng Yahe (intern)

- END -